

Table Of Contents:

- Dedication
- Preface
 - Preface to Second Edition
 - Preface to First Edition
- Chapter 1: Introduction
 - Abstract
 - 1.1 Drug-like Properties in Drug Discovery
 - 1.2 Purpose of This Book
 - Problems
- Chapter 2: Benefits of Property Assessment and Good Drug-Like Properties
 - Abstract
 - 2.1 Introduction
 - 2.2 Discovery Scientists Optimize Many Properties
 - 2.3 Introduction to the Drug Discovery and Development Process
 - 2.4 Benefits of Good Drug-like Properties
 - 2.5 Property Profiling in Drug Discovery
 - 2.6 Drug-like Property Optimization in Drug Discovery
 - Problems
- Chapter 3: In Vivo Environments Affect Drug Exposure
 - Abstract
 - 3.1 Introduction
 - 3.2 Drug Dosing
 - 3.3 Stomach
 - 3.4 Intestinal Environment
 - 3.5 Bloodstream
 - 3.6 Liver
 - 3.7 Kidney
 - 3.8 Blood-Tissue Barriers
 - 3.9 Tissue Distribution
 - 3.10 Consequences of Chirality
 - 3.11 Overview of in vivo Challenges to Drug Exposure
 - Problems
- Chapter 4: Prediction Rules for Rapid Property Profiling from Structure
 - Abstract
 - 4.1 Introduction
 - 4.2 General Concepts for Prediction Rules
 - 4.3 Rule of 5
 - 4.4 Veber Rules
 - 4.5 Waring Rules
 - 4.6 Golden Triangle
 - 4.7 Other Predictive Rules
 - 4.8 Application of Rules for Compound Assessment
 - 4.9 Applications of Predictive Rules
 - Problems
- Chapter 5: Lipophilicity
 - Abstract
 - 5.1 Lipophilicity Fundamentals
 - 5.2 Lipophilicity Effects
 - 5.3 Lipophilicity Case Studies and Structure Modification
 - Problems
- Chapter 6: pK_a
 - Abstract
 - 6.1 pK_a Fundamentals
 - 6.2 pK_a Effects
 - 6.3 pK_a Case Studies
 - 6.4 Structure Modification Strategies for pK_a
 - Problems
- Chapter 7: Solubility
 - Abstract
 - 7.1 Introduction
 - 7.2 Solubility Fundamentals

- 7.3 Effects of Solubility
- 7.4 Effects of Physiology on Solubility and Absorption
- 7.5 Structure Modification Strategies to Improve Solubility
- 7.6 Strategies to Improve Dissolution Rate
- 7.7 Salt Form
- 7.8 Strategy for Solubility During Drug Discovery
- Problems
- Chapter 8: Permeability
 - Abstract
 - 8.1 Introduction
 - 8.2 Permeability Fundamentals
 - 8.3 Permeability Effects
 - 8.4 Permeability Structure Modification Strategies
 - 8.5 Strategy for Permeability
 - Problems
- Chapter 9: Transporters
 - Abstract
 - 9.1 Introduction
 - 9.2 Transporter Fundamentals
 - 9.3 Transporter Effects
 - 9.4 Efflux Transporters
 - 9.5 Uptake Transporters
 - Problems
- Chapter 10: Blood-Brain Barrier
 - Abstract
 - 10.1 Introduction
 - 10.2 Fundamentals of Brain Exposure
 - 10.3 Effects of Brain Exposure on Efficacy and Drug Development
 - 10.4 Structure-Passive Transcellular BBB Permeation Relationships
 - 10.5 Structure Modification Strategies to Improve BBB Permeation
 - 10.6 Applications of Brain Exposure
 - Problems
- Chapter 11: Metabolic Stability
 - Abstract
 - 11.1 Introduction
 - 11.2 Metabolic Stability Fundamentals
 - 11.3 Metabolic Stability Effects
 - 11.4 Structure Modification Strategies for Phase I CYP Metabolic Stability
 - 11.5 Structure Modification Strategies for Phase II Metabolic Stability
 - 11.6 Applications of Metabolic Stability Data
 - 11.7 Consequences of Chirality on Metabolic Stability
 - 11.8 Substrate Specificity of CYP Isozymes
 - 11.9 Aldehyde Oxidase
 - Problems
- Chapter 12: Plasma Stability
 - Abstract
 - 12.1 Introduction
 - 12.2 Plasma Stability Fundamentals
 - 12.3 Effects of Plasma Instability
 - 12.4 Structure Modification Strategies to Improve Plasma Stability
 - 12.5 Strategies for Plasma Stability
 - Problems
- Chapter 13: Solution Stability
 - Abstract
 - 13.1 Introduction
 - 13.2 Solution Stability Fundamentals
 - 13.3 Effects of Solution Instability
 - 13.4 Solution Stability Case Studies
 - 13.5 Structure Modification Strategies to Improve Solution Stability
 - 13.6 Applications of Solution Stability in Drug Discovery
 - Problems
- Chapter 14: Plasma and Tissue Binding
 - Abstract
 - 14.1 Introduction
 - 14.2 Drug Binding in Plasma

- 14.3 Drug Binding in Tissue
- 14.4 Free Drug Hypothesis
- 14.5 Pharmacokinetics Principles of Oral Drugs Relevant to Drug Binding
- 14.6 The Useful Application of f_u
- 14.7 Misconceptions and Unproductive Strategies for PPB
- 14.8 Best Practices Regarding PPB and Tissue Binding
- Problems
- Chapter 15: Cytochrome P450 Inhibition
 - Abstract
 - 15.1 Introduction
 - 15.2 CYP Inhibition Fundamentals
 - 15.3 Effects of CYP Inhibition
 - 15.4 CYP Inhibition Case Studies
 - 15.5 Structure Modification Strategies to Reduce CYP Inhibition
 - 15.6 Other DDIs
 - 15.7 Regulatory Guidance on DDI
 - 15.8 Applications of CYP Inhibition
 - Problems
- Chapter 16: hERG Blocking
 - Abstract
 - 16.1 Introduction
 - 16.2 hERG Fundamentals
 - 16.3 hERG Blocking Effects
 - 16.4 hERG Blocking SAR
 - 16.5 Structure Modification Strategies for hERG
 - 16.6 Applications of hERG Blocking Assessment
 - Problems
- Chapter 17: Toxicity
 - Abstract
 - 17.1 Introduction
 - 17.2 Toxicity Fundamentals
 - 17.3 Toxic Effect Categories
 - 17.4 Examples of Toxicity Effects
 - 17.5 In Vivo Toxicity
 - 17.6 Case Studies of Toxicity in Drug Discovery
 - 17.7 Rules for Off-Target Toxicity by Drug Discovery Compounds
 - 17.8 Relationship of C_{max} to in vivo Toxicity of Drug Discovery Compounds
 - 17.9 Structure Modification Strategies to Improve Safety
 - Problems
- Chapter 18: Integrity and Purity
 - Abstract
 - 18.1 Introduction
 - 18.2 Fundamentals of Integrity and Purity
 - 18.3 Integrity and Purity Effects
 - 18.4 Applications of Integrity and Purity
 - Problems
- Chapter 19: Pharmacokinetics
 - Abstract
 - 19.1 Introduction
 - 19.2 PK Parameters
 - 19.3 Tissue Concentration
 - 19.4 Using PK Data in Drug Discovery
 - 19.5 Relationship of PK to PD
 - 19.6 Applications of PK
 - Problems
- Chapter 20: Lead Properties
 - Abstract
 - 20.1 Introduction
 - 20.2 Lead-like Properties
 - 20.3 Template Property Conservation
 - 20.4 Including Properties in Hit Triage
 - 20.5 Fragment-based Screening
 - 20.6 Ligand Lipophilicity Efficiency
 - 20.7 Conclusions

- Problems
- Chapter 21: Strategies for Integrating Drug-Like Properties into Drug Discovery
 - Abstract
 - 21.1 Introduction
 - 21.2 Start Assessing Drug Properties Early to Prioritize Compounds and Plan Structure Modifications
 - 21.3 Assess Drug Properties for all New Compounds Rapidly
 - 21.4 Develop Structure-Property Relationships
 - 21.5 Optimize Activity and Properties in Parallel
 - 21.6 Use Single-property Assays to Guide Specific Modifications
 - 21.7 Use Complex Property Methods for Decision-making and Human Modeling
 - 21.8 Apply Property Data to Improve Biological Experiments
 - 21.9 Use Customized Assays to Answer Specific Research Questions
 - 21.10 Diagnose the Root Cause of Inadequate Pharmacokinetics
 - 21.11 Run in vitro Assays Using Human Materials to Predict Human Performance
 - Problems
- Chapter 22: Methods for Profiling Drug-Like Properties: General Concepts
 - Abstract
 - 22.1 Introduction
 - 22.2 It is Valuable for Medicinal Chemists to Understand the ADMET Assays and Collaborate with ADMET Scientists
 - 22.3 Choose an Ensemble of Key Properties to Evaluate
 - 22.4 Use Relevant Assay Conditions
 - 22.5 Property Data Should Be Readily Available
 - 22.6 Evaluate the Cost-benefit Ratio for Assays
 - 22.7 Use Well Developed Assays that Are Well Validated
 - Problems
- Chapter 23: Lipophilicity Methods
 - Abstract
 - 23.1 In Silico Lipophilicity Methods
 - 23.2 Lipophilicity Methods
 - 23.3 In-Depth Lipophilicity Methods
 - Problems
- Chapter 24: pK_a Methods
 - Abstract
 - 24.1 Introduction
 - 24.2 In Silico pK_a Methods
 - 24.3 Laboratory pK_a Methods
 - Problems
- Chapter 25: Solubility Methods
 - Abstract
 - 25.1 Introduction
 - 25.2 Solubility Calculation Estimation
 - 25.3 Software for Solubility
 - 25.4 Kinetic Solubility Methods
 - 25.5 Thermodynamic Solubility Methods
 - 25.6 Customized Solubility Methods
 - 25.7 Dissolution Rate Measurement
 - 25.8 DMSO Solubility
 - 25.9 Commercial CRO Labs Offering Solubility Measurement
 - 25.10 Strategy for Solubility Measurement
 - Problems
- Chapter 26: Permeability Methods
 - Abstract
 - 26.1 Introduction
 - 26.2 Computational Prediction of Permeability
 - 26.3 In Vitro Permeability Methods
 - 26.4 In-Depth Permeability Methods
 - 26.5 Applications of Permeability in Drug Discovery
 - Problems
- Chapter 27: Transporter Methods
 - Abstract
 - 27.1 Introduction
 - 27.2 In Silico Transporter Methods

- 27.3 In Vitro Transporter Methods
 - 27.4 In Vivo Methods for Transporters
 - Problems
- Chapter 28: Blood-Brain Barrier Methods
 - Abstract
 - 28.1 Introduction
 - 28.2 Methods for BBB Permeability
 - 28.3 Methods for Brain Binding and Distribution
 - 28.4 Applications of BBB Permeation and Brain Distribution Methods
 - Problems
- Chapter 29: Metabolic Stability Methods
 - Abstract
 - 29.1 Introduction
 - 29.2 Metabolic Stability Methods
 - 29.3 In Silico Metabolic Stability Methods
 - 29.4 In Vitro Metabolic Stability Methods
 - Problems
- Chapter 30: Plasma Stability Methods
 - Abstract
 - 30.1 Introduction
 - 30.2 General Protocol for in vitro Plasma Stability
 - 30.3 Low-throughput Method for in vitro Plasma Stability
 - 30.4 High-throughput Method for in vitro Plasma Stability
 - 30.5 Structure Elucidation of Plasma Degradation Products
 - 30.6 Strategies for Plasma Stability Measurement
 - Problems
- Chapter 31: Solution Stability Methods
 - Abstract
 - 31.1 Introduction
 - 31.2 Methodology for Solution Stability Measurement
 - 31.3 Method for Solution Stability in Biological Assay Media
 - 31.4 Example Methods from the Literature for pH Solution Stability
 - 31.5 Methods for Solution Stability in Simulated GI Fluids
 - 31.6 Identification of Degradation Products from Solution Stability Assays
 - 31.7 In-depth Solution Stability Assessment in Late Stage Drug Discovery
 - 31.8 Strategy for Solution Stability Assessment
 - Problems
- Chapter 32: CYP Inhibition Methods
 - Abstract
 - 32.1 Introduction
 - 32.2 In Silico CYP Inhibition Methods
 - 32.3 In Vitro Reversible CYP Inhibition Methods
 - 32.4 In Vitro Irreversible (TDI) CYP Inhibition Methods
 - 32.5 CYP Inhibition Method Applications
 - Problems
- Chapter 33: Plasma and Tissue Binding Methods
 - Abstract
 - 33.1 Introduction
 - 33.2 In Silico Plasma Protein Binding Methods
 - 33.3 In Vitro Binding Methods
 - 33.4 Red Blood Cell Binding
 - 33.5 Contract Research Laboratories for Protein Binding Assays
 - Problems
- Chapter 34: hERG Methods
 - Abstract
 - 34.1 Introduction
 - 34.2 In Silico hERG Methods
 - 34.3 In Vitro hERG Methods
 - 34.4 Ex Vivo Methods for hERG Blocking
 - 34.5 In Vivo Electrocardiography Telemetry for hERG Blocking
 - 34.6 Applications of hERG Blocking Methods in Drug Discovery
 - Problems
- Chapter 35: Toxicity Methods
 - Abstract
 - 35.1 Introduction

- 35.2 In Silico Toxicity Methods
- 35.3 In Vitro Toxicity Methods
- 35.4 In Vivo Toxicity Methods
- Problems
- Chapter 36: Integrity and Purity Methods
 - Abstract
 - 36.1 Introduction
 - 36.2 Samples for Integrity and Purity Profiling
 - 36.3 Requirements of Integrity and Purity Profiling Methods
 - 36.4 Integrity and Purity Method Characteristics
 - 36.5 Follow Up on Negative Identity Results
 - 36.6 Example Generic High-Throughput Purity and Integrity Method
 - 36.7 Purity and Integrity Case Studies
 - Problems
- Chapter 37: Pharmacokinetic Methods
 - Abstract
 - 37.1 Introduction
 - 37.2 Dosing for PK Studies
 - 37.3 PK Sampling and Sample Preparation
 - 37.4 LC/MS/MS Analysis
 - 37.5 Advanced PK Studies
 - 37.6 Example Pharmacokinetic Data
 - 37.7 Tissue Penetration
 - 37.8 Unbound Drug Concentration in Plasma or Tissue
 - 37.9 Contract Research Laboratories
 - Problems
- Chapter 38: Diagnosing and Improving Pharmacokinetic Performance
 - Abstract
 - 38.1 Introduction
 - 38.2 Diagnosing Underlying Property Limitations from PK Performance
 - 38.3 Case Studies on Diagnosing Unfavorable PK Behavior
 - Problems
- Chapter 39: Prodrugs
 - Abstract
 - 39.1 Introduction
 - 39.2 Prodrug Design Differs with the ADME Process and Administration Route
 - 39.3 Using Prodrugs to Improve Solubility
 - 39.4 Prodrugs to Increase Passive Permeability
 - 39.5 Transporter-Mediated Prodrugs to Enhance Intestinal Absorption
 - 39.6 Prodrugs to Reduce Metabolism
 - 39.7 Prodrugs to Target Specific Tissues
 - 39.8 Soft Drugs
 - Problems
- Chapter 40: Effects of Properties on Biological Assays
 - Abstract
 - 40.1 Introduction
 - 40.2 Effects of Insolubility in DMSO
 - 40.3 Dealing with Insolubility in DMSO
 - 40.4 Effects of Insolubility in Aqueous Buffers
 - 40.5 Dealing with Insolubility in Aqueous Buffers
 - Problems
- Chapter 41: Formulation
 - Abstract
 - 41.1 Introduction
 - 41.2 Routes of Administration
 - 41.3 Potency Drives Delivery Opportunities
 - 41.4 Formulation Strategies
 - 41.5 Practical Guide for Formulation in Drug Discovery
 - Problems
- Appendix I: Answers to Chapter Problems
 - Chapter 1—Introduction
 - Chapter 2—Benefits of Property Assessment and Good Drug-like Properties
 - Chapter 3—In Vivo Environments Affect Drug Exposure
 - Chapter 4—Prediction Rules for Rapid Property Profiling From Structure
 - Chapter 5—Lipophilicity

- Chapter 6— pK_a
- Chapter 7—Solubility
- Chapter 8—Permeability
- Chapter 9—Transporters
- Chapter 10—Blood-Brain Barrier
- Chapter 11—Metabolic Stability
- Chapter 12—Plasma Stability
- Chapter 13—Solution Stability
- Chapter 14—Plasma Protein Binding
- Chapter 15—Cytochrome P450 Inhibition
- Chapter 16—hERG Blocking
- Chapter 17—Toxicity
- Chapter 18—Purity and Integrity
- Chapter 19—Pharmacokinetics
- Chapter 20—Lead Properties
- Chapter 21—Strategies for Integrating Drug-like Properties into Drug Discovery
- Chapter 22—Methods for Profiling Drug-like Properties: General Concepts
- Chapter 23—Lipophilicity Methods
- Chapter 24— pK_a Methods
- Chapter 25—Solubility Methods
- Chapter 26—Permeability Methods
- Chapter 27—Transporter Methods
- Chapter 28—Blood-Brain Barrier Methods
- Chapter 29—Metabolic Stability Methods
- Chapter 30—Plasma Stability Methods
- Chapter 31—Solution Stability Methods
- Chapter 32—CYP Inhibition Methods
- Chapter 33—Plasma Tissue Binding Methods
- Chapter 34—hERG Methods
- Chapter 35—Toxicity Methods
- Chapter 36—Integrity and Purity Methods
- Chapter 37—Pharmacokinetic Methods
- Chapter 38—Diagnosing and Improving Pharmacokinetic Performance
- Chapter 39—Prodrugs
- Chapter 40—Effects of Properties on Biological Assays
- Chapter 41—FORMULATION
- Appendix II: General Reference Books
- Appendix III: Glossary
- Index